Bruker Co. (NASDAQ:BRKR) Shares Bought by Eagle Bay Advisors LLC

Eagle Bay Advisors LLC increased its stake in Bruker Co. (NASDAQ:BRKRFree Report) by 2,324.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 703 shares of the medical research company’s stock after buying an additional 674 shares during the period. Eagle Bay Advisors LLC’s holdings in Bruker were worth $41,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC raised its stake in shares of Bruker by 133.8% in the 2nd quarter. Quest Partners LLC now owns 3,343 shares of the medical research company’s stock valued at $213,000 after purchasing an additional 1,913 shares in the last quarter. American Century Companies Inc. raised its stake in Bruker by 6.2% during the second quarter. American Century Companies Inc. now owns 30,223 shares of the medical research company’s stock valued at $1,929,000 after buying an additional 1,776 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Bruker by 5.3% during the 2nd quarter. Federated Hermes Inc. now owns 166,561 shares of the medical research company’s stock worth $10,628,000 after buying an additional 8,346 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Bruker by 48.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 301,251 shares of the medical research company’s stock worth $19,223,000 after acquiring an additional 98,427 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Bruker by 22.6% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 430,338 shares of the medical research company’s stock valued at $27,460,000 after acquiring an additional 79,340 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. TD Cowen lowered their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Guggenheim started coverage on Bruker in a research report on Thursday, December 19th. They issued a “buy” rating and a $72.00 target price on the stock. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a research report on Thursday, December 5th. Finally, UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $74.45.

Check Out Our Latest Stock Analysis on BRKR

Insider Activity

In related news, CEO Frank H. Laukien bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 28.30% of the company’s stock.

Bruker Stock Up 3.6 %

Shares of BRKR stock opened at $62.95 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The stock has a market cap of $9.54 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 4.00 and a beta of 1.17. The business’s fifty day moving average is $57.87 and its 200-day moving average is $61.77. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86.

Bruker (NASDAQ:BRKRGet Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter last year, the firm posted $0.74 earnings per share. Bruker’s revenue was up 16.4% compared to the same quarter last year. Equities analysts expect that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.32%. Bruker’s dividend payout ratio is currently 9.62%.

Bruker Company Profile

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Further Reading

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.